A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is compare the relative bioavailability of 10 mg Citalopram
Hydrobromide tablets by Purepac Pharmaceutical Co with that of 10 mg CELEXATM tablets
distributed and marketed by Forest Pharmaceuticals, Inc. following a single oral dose (1 x 10
mg tablet) in healthy adult volunteers under fasting conditions